New Molecular Diagnostic Products

A multiplex analyte specific reagent (ASR) designed for the detection of Factor V Leiden and Factor II Prothrombin gene mutations associated with cardiovascular disease and thrombosis are available for high complexity laboratories, which can use the reagents to create and validate laboratory-developed tests for the detection of these mutations.

The ASR is the product of Nanogen, Inc. (San Diego, CA, USA), a provider of molecular diagnostic products. The company has also launched the Assay ToolBox, a set of consumable products that allows customers to define, select, and build their own assays. The ToolBox complements the open-architecture of Nanogen's NanoChip electronic microarray.

The FactorV/Factor II Prothrombin ASR consists of reagents, controls, and analysis of the G1691A mutation on the Factor V (Leiden) gene and the G20210A mutation on the Prothrombin gene. Carriers of the Factor II mutation have a three- to eight-fold increased risk for blood clot formation, and the risk is significantly greater in those who also carry the Factor V Leiden Mutation. Recently, Nanogen also launched ASRs for the detection of the CFTR gene for cystic fibrosis and the HFE gene for hereditary hemochromatosis.

"Our aim is to deliver a solid testing platform with the broadest possible menu,” said Howard Birndorf, chairman and CEO of Nanogen.




Related Links:
Nanogen